Scientists from the Scripps Research Institute have discovered the key chemical that signals Bacillus anthracis, the bacterium that causes anthrax, to become lethal. This finding opens up new avenues of exploration for the development of treatments for bacterial infections. The study was published in the November 21 edition of the journal PLoS Pathogens . The
Full Post: Scientists identify blood component that turns anthrax bacteria virulent
Research by a Michigan State University chemist could eventually lead to a quicker and easier way of developing protein-based drugs that are key to treating a number of diseases, including cancer, diabetes and hepatitis.
Proteins used in drug manufacture and research often are made within genetically modified Escherichia coli , a one-cell bacteria. That protein tends to collect into what scientists call inclusion bodies. Those hard-to-separate clumps render up to 95 percent of the protein unusable, according to associate chemistry professor David P. Weliky.
Some can be recovered by breaking down the protein to separate it, but because protein structure determines its function, another step must be added to “refold” it into its original configuration.
Weliky and colleagues took a closer look at the structure of the proteins that make up these inclusion bodies. Learning what makes them stick together might yield some clues as to how to separate them, he said, and that could make the manufacturing process more efficient.
Instead of employing more commonly used infrared spectroscopy to look at dehydrated samples, the researchers used nuclear magnetic resonance spectroscopy using whole cells. That technology analyzes the magnetic properties of an atom’s nucleus.
While best known as medical diagnostic imaging technology, Weliky and colleagues view NMR as a powerful approach to analyzing biological molecules, including bacterial inclusion bodies. Because the inclusion body protein appeared to be predominantly folded rather than unfolded, it might be possible to extract protein without separating and then refolding, Weliky said.
“This study highlights our ability to probe the molecular structure of a single protein in whole cells and to apply advanced analytical and biochemical methods to a problem of general significance in biotechnology,” Weliky said.
http://www.msu.edu/
--------------------------------------------------------------------------------------------
Related Posts:
IMRIS Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s 3 Tesla IMRISneuro for sale in the U.S. IMRISneuro is now available with either a 1.5 Tesla (1.5T) or a 3 Tesla (3T) magnet. Both systems provide IMRIS’ patented technology and utilize 70 cm wide bore advanced magnetic resonance
Full Post: IMRIS receives FDA clearance for 3 Tesla IMRISneuro
Research led by Iowa State University scientists has them a step closer to finding a way to counter the Ebola virus. A team led by Gaya Amarasinghe, an assistant professor in biochemistry, biophysics and molecular biology, has recently solved the structure from a key part of the Ebola protein known as VP35. VP35 interferes with
Full Post: Researchers solve structure of key Ebola protein
A study published in the scientific journal PLoS ONE highlights how the exploration of the ocean depths can benefit humankind. This is the story of a voyage of discovery, starting with marine animals that glow, the identification of the molecules responsible and their application as marker in living cells. Many marine organisms such as sea
Full Post: Biomedical research could benefit from deep sea
Scientists at St. Jude Children’s Research Hospital have gained new insights into regulation of one of the body’s enzyme workhorses called calpains. As the cell’s molecular overachievers, calpains function in many cellular processes, including the movement of cells in tissues, the death of damaged cells, insulin secretion, and brain cell and muscle function. The downside
Full Post: Scientists gain new insights into regulation of calpains
A team led by Stanford researchers has developed a prototype blood scanner that can find cancer markers in the bloodstream in early stages of the disease, potentially allowing for earlier treatment and dramatically improved chances of survival. The system based on MagArray biodetection chips can find cancer-associated proteins in a blood serum sample in less
Full Post: Prototype blood scanner detects even faint indicators of cancer --------------------------------------------------------------------------------------------
